Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: limitations and opportunities

被引:3
作者
Koehm, Michaela [1 ,2 ,3 ]
Behrens, Frank [1 ,2 ,3 ]
机构
[1] Goethe Univ Frankfurt, Div Translat Rheumatol, Immunol, Inflammat Med, Frankfurt, Hessen, Germany
[2] Fraunhofer Inst Translat Med & Pharmacol ITMP, Clin Res, Frankfurt, Germany
[3] Fraunhofer Cluster Excellence Immune Mediated Dis, Clin Res, Frankfurt, Germany
关键词
arthritis; psoriatic; anti-inflammatory agents; non-steroidal; inflammation;
D O I
10.1136/rmdopen-2023-003166
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Psoriatic arthritis (PsA) is a chronic inflammatory immune-mediated disease that affects approximately 30% of psoriasis patients. In most cases, skin disease clearly precedes the musculoskeletal disease. Some studies suggest that targeted treatment may intercept the disease course and prevent psoriasis patients from developing PsA. A recent population-based retrospective analysis in 15 501 psoriasis patients evaluated the association between different biological treatment strategies and time to incident inflammatory arthritis based on data in a US electronic health records database. A cumulative incidence of 2.6 PsA cases per 100 person-years was determined. The multivariable regression analysis revealed a significantly lower risk of developing inflammatory arthritis in patients who had been prescribed interleukin (IL)-12/23 or IL-23 inhibitors compared with tumour necrosis factor (TNF) inhibitor-treated patients, whereas there was no significant difference in risk for patients prescribed inhibitors of IL-17 versus TNF. Although the analysis was based on a large set of clinical data and the findings were rigorously evaluated, there are some limitations in interpretation due to the study design. Prospective clinical trials are missing, and retrospective data analyses from clinical trials or population-based studies show conflicting results. Overall, the recent data on prevention of PsA in patients with psoriasis support the high need to characterise biomarkers of increased risk and perform prospective clinical trials to give a clear guidance on possibilities for disease interception in psoriatic disease.
引用
收藏
页数:4
相关论文
共 23 条
[1]   Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis [J].
Acosta Felquer, Maria Laura ;
LoGiudice, Luciano ;
Laura Galimberti, Maria ;
Rosa, Javier ;
Mazzuoccolo, Luis ;
Soriano, Enrique R. .
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (01) :74-79
[2]   Ultrasound Enthesitis in Psoriasis Patients with or without Psoriatic Arthritis, a Cross-Sectional Analysis [J].
Agache, Mihaela ;
Popescu, Claudiu C. ;
Popa, Liliana ;
Codreanu, Catalin .
MEDICINA-LITHUANIA, 2022, 58 (11)
[3]   Do Biologic Treatments for Psoriasis Lower the Risk of Psoriatic Arthritis? A Systematic Review [J].
Aronovich, Anna ;
Novikov, Ilya ;
Pavlovsky, Lev .
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2023, 24 (06) :865-873
[4]   The role of IL-23 and the use IL-23 inhibitors in psoriatic arthritis [J].
Fragoulis, George E. ;
Siebert, Stefan .
MUSCULOSKELETAL CARE, 2022, 20 :S12-S21
[5]   Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis [J].
Gisondi, Paolo ;
Bellinato, Francesco ;
Targher, Giovanni ;
Idolazzi, Luca ;
Girolomoni, Giampiero .
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 (01) :68-73
[6]   Psoriatic arthritis: epidemiology, clinical features, course, and outcome [J].
Gladman, DD ;
Antoni, C ;
Mease, P ;
Clegg, DO ;
Nash, P .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 :14-17
[7]   Omics and Multi-Omics Analysis for the Early Identification and Improved Outcome of Patients with Psoriatic Arthritis [J].
Gurke, Robert ;
Bendes, Annika ;
Bowes, John ;
Koehm, Michaela ;
Twyman, Richard M. ;
Barton, Anne ;
Elewaut, Dirk ;
Goodyear, Carl ;
Hahnefeld, Lisa ;
Hillenbrand, Rainer ;
Hunter, Ewan ;
Ibberson, Mark ;
Ioannidis, Vassilios ;
Kugler, Sabine ;
Lories, Rik J. ;
Resch, Eduard ;
Rueping, Stefan ;
Scholich, Klaus ;
Schwenk, Jochen M. ;
Waddington, James C. ;
Whitfield, Phil ;
Geisslinger, Gerd ;
FitzGerald, Oliver ;
Behrens, Frank ;
Pennington, Stephen R. .
BIOMEDICINES, 2022, 10 (10)
[8]   Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial [J].
Haberman, Rebecca H. ;
MacFarlane, Katrina A. ;
Catron, Sydney ;
Samuels, Jonathan ;
Blank, Rebecca B. ;
Toprover, Michael ;
Uddin, Zakwan ;
Hu, Jiyuan ;
Castillo, Rochelle ;
Gong, Cinty ;
Qian, Kun ;
Piguet, Vincent ;
Tausk, Francisco ;
Yeung, Jensen ;
Neimann, Andrea L. ;
Gulliver, Wayne ;
Thiele, Ralf G. ;
Merola, Joseph F. ;
Ogdie, Alexis ;
Rahman, Proton ;
Chakravarty, Soumya D. ;
Eder, Lihi ;
Ritchlin, C. T. ;
Scher, Jose U. .
BMJ OPEN, 2022, 12 (12)
[9]   Dactylitis: A hallmark of psoriatic arthritis [J].
Kaeley, Gurjit S. ;
Eder, Lihi ;
Aydin, Sibel Z. ;
Gutierrez, Marwin ;
Bakewell, Catherine .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2018, 48 (02) :263-273
[10]   Innovative Imaging Technique for Visualization of Vascularization and Established Methods for Detection of Musculoskeletal Inflammation in Psoriasis Patients [J].
Koehm, Michaela ;
Zerweck, Lukas ;
Ngyuen, Phuong-Ha ;
Burkhardt, Harald ;
Behrens, Frank .
FRONTIERS IN MEDICINE, 2020, 7